Expanding the DNA alphabet: ‘extra’ DNA base found to be stable
A rare DNA base, previously thought to be a temporary modification, has been shown to be stable in mammalian DNA, suggesting that it plays a key role in cellular function.
Researchers from the University of Cambridge and the Babraham Institute have found that a naturally occurring modified DNA base appears to be stably incorporated in the DNA of many mammalian tissues, possibly representing an expansion of the functional DNA alphabet.
The new study, published today in the journal Nature Chemical Biology, has found that this rare ‘extra’ base, known as 5-formylcytosine (5fC) is stable in living mouse tissues. While its exact function is yet to be determined, 5fC’s physical position in the genome makes it likely that it plays a key role in gene activity.
“If 5fC is present in the DNA of all tissues, it is probably there for a reason,” said Professor Shankar Balasubramanian of the Department of Chemistry and the Cancer Research UK Cambridge Institute, who led the research. “It had been thought this modification was solely a short-lived intermediate, but the fact that we’ve demonstrated it can be stable in living tissue shows that it could regulate gene expression and potentially signal other events in cells.”
Related News
See all news-
Imaging technique allows rapid assessment of ovarian cancer subtypes and their response to treatment
6th December 2024
An MRI-based imaging technique developed at the Institute predicts the response of ovarian cancer tumours to treatment, and rapidly reveals how well treatment is working, in patient-derived cell models.
Find out more -
Isabel Esain Garcia awarded PhD Thesis Prize
3rd December 2024
The Prize is awarded annually to a student who has undertaken an outstanding research project to the highest standards during the course of their PhD study at the Cancer Research UK Cambridge Institute.
Find out more -
World first trial to revolutionise treatment of brain cancer
23rd October 2024
A pioneering research study will trial multiple new treatments for people in the UK living with glioblastoma, an aggressive form of brain cancer.
Find out more